Even though Chinese biopharma assets are increasingly licensed globally by Western pharmaceutical companies, that does not mean Chinese biotechs are becoming global multinationals. Industry commentary notes that until Chinese companies enter the U.S. market as product owners operating on their own balance sheet and profit-and-loss structure, building a truly global multinational from within China will remain a much slower process.
Washington policymakers and Treasury officials are less concerned about multinational companies simply buying or licensing therapeutic assets from Chinese biotechs. Instead, scrutiny under legislative frameworks like the COINS Act focuses on co-development arrangements, where Western pharmas could help Chinese partners build internal capabilities that allow them to eventually compete against American companies.
Historically, multinational drugmakers sourced clinical-stage oncology antibodies and antibody-drug conjugates from China. Recent multibillion-dollar transactions from Novartis, Merck, and Novo Nordisk signal a shift toward acquiring preclinical-stage assets across diverse disease areas and novel modalities—such as mRNA-encoded T-cell engagers and molecular glues—demonstrating increasing Western confidence in early-stage, potentially first-in-class Chinese discovery.
Although the Trump administration's GLOBE model shrank from an anticipated $11.9 billion in savings to roughly $440 million impacting only a handful of companies, its true danger to biopharma is precedent. Pharma agreements endorsing foreign prices as valid benchmarks for U.S. reimbursement give policymakers enduring leverage to justify international reference pricing and direct executive price negotiations in future Medicare programs.
Nobel laureate Karl Deisseroth highlighted that solving intractable brain disorders like Alzheimer's or schizophrenia will not come from top-down, targeted moonshot initiatives. Breakthroughs are far more likely to emerge unexpectedly from foundational basic research across disparate fields and the creation of enabling tools—such as optogenetics and tissue-clearing methods—that allow researchers to ask entirely new mechanistic questions.
Beam Therapeutics' trade secret lawsuit against Yoltec includes claims of misappropriated negative know-how, arguing that knowing what did not work enabled Yoltec to develop an AATD therapy faster. However, proving negative know-how before a jury is extremely challenging, especially when defendants can cite prior public domain disclosures, independent contemporaneous research records, and normal fast-following practices.